Isocarboxazid is a nonselective and irreversible antidepressant. It is a type of drug that inhibits the action of monoamine oxidase enzyme and belongs to the hydrazine class. It is primarily used for the treatment of anxiety and depression and is specifically used when all other treatments fail to show any clinical response. It has been approved in the U.S. for the treatment of depression and licensed for the treatment of depression in the UK, when a person is unresponsive to selective serotonin reuptake inhibitors.
The isocarboxazid market is anticipated to grow significantly during the forecast period owing to various driving factors. The emergence of COVID-19 witnessed an increase in major depressive disorder and anxiety disorder cases globally. This pandemic specifically affected the more vulnerable population like people living in poverty, older people, people with disabilities, youth, and indigenous peoples. Millions of workers; waged and self-employed, regularly faced high levels of working poverty, loss of economy, and educational crisis. Most of the population felt lonely, frustrated, and vulnerable, physically, emotionally, and financially which ultimately led to depressive episodes. During this period, the market share of antidepressant drugs expanded gradually. Among these, isocarboxazid market showed good sales during the pandemic period. Some people, even after being treated with antidepressants do not show any clinical response. At this time, isocarboxazid drugs can be used for the treatment of major depressive disorder. Hence, the unresponsiveness of other antidepressants and treatment-resistant depression may also act as a driver for this market. Furthermore, there are various biologic innovations and novel technologies for the treatment of depression. Since there is an increase in mental disorders, which is also life-threatening, various organizations have taken interest in funding research for newer therapies with minimal side effects. These may help to expand this market in the forecast period.
Although the isocarboxazid market is witnessing an upsurge, some restraints may hinder the growth of the market. Isocarboxazid usage is accompanied by several adverse effects. At the beginning of treatment, some patients—especially those who are younger than 24—may have suicidal thoughts. Other common side effects include fainting, mood changes, muscle stiffness, changes in sexual ability or interest, shivering, swollen ankles or legs, unusual weight gain, and vision changes like double or blurred vision. A serious interaction between this, and other medications, such as antibiotics and some other antidepressants, may occur. Therefore, it is critical to take caution when administering other drugs. Moreover, severe withdrawal symptoms such as agitation, confusion, hallucinations, headache, weakness, and diarrhea may emerge if this medicine is discontinued abruptly. These factors could limit this market's growth. In addition, these medications could be expensive hence making them accessible to a small group. All these factors are predicted to impede the market's expansion for isocarboxazid.
According to the 2021 anxiety and depression Association of America report, anxiety was found to be one of the most common disorders in the U.S.. This can create various new opportunities for key players to expand the isocarboxazid market. Isocarboxazid is mainly used when all other treatments fail to show any effect, this may also help the expansion of this market. The increasing cases of depression, especially post-pandemic has also created new opportunities. New product launches as well as new research for novel treatments with fewer side effects may drive the demand for isocarboxazid market
`
New product launches to flourish in the market
Segment Overview: In hospital pharmacy, patients receive their isocarboxazid prescriptions straight from the hospital. A hospital pharmacy provides medical services like compounding and dispensing of the drug. These services are offered to both inpatients and outpatients; inpatients are those who are admitted to the same hospital, whilst outpatients are those who visit the hospital for a checkup or treatment. Online pharmacies have rapidly become popular in recent years. Most people prefer to order their medications online to avoid having to travel to a physical pharmacy. However, there can be some drawbacks to this kind of channel of distribution. There have been multiple cases of unregistered or unlicensed pharmacies dispensing adulterated, spurious, or mislabeled drugs. In addition, online pharmacies do not offer the required consultation for such medications that are often offered at retail or hospital pharmacies. Antidepressants may also be lethal if the correct dosage is not given. These factors could all limit how widely isocarboxazid is distributed online. Retail pharmacies are those that dispense medical supplies and prescription medications to the general public. While dispensing medication, it must be checked if the patient is carrying a proper prescription given by a registered medical practitioner.
Competitive analysis and profiles of the major players in the isocarboxazid market, such as Amneal Pharmaceuticals, Inc., Chemspec chemicals private limited, GlaxoSmithKline plc, Jigs Chemical, Medilink, Parke-Davis, Roberts Laboratories, Schering, Validus Pharmaceuticals LLC, Zeneca are provided in this report.
Key Market Segments
- By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Malaysia
- Indonesia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- UAE
- Argentina
- Rest of LAMEA
Key Market Players
- Roberts Laboratories
- Validus Pharmaceuticals LLC
- Parke-Davis
- Schering
- Jigs Chemical
- Amneal Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Medilink
- chemspec chemicals private limited
- Zeneca